Skip to main content

Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy

Virchows Archiv volume 478, pages 1161–1171 (2021)Cite this article

Abstract

Uterine carcinosarcoma (UCS) is an uncommon and highly aggressive tumor. There is no HER2 testing protocol for UCS despite the development of HER2 antibody conjugates. We aimed to elucidate histopathological HER2 expression details in UCS, to compare HER2 scores between ASCO/CAP criteria for gastric and breast cancer, and to propose requirements for HER2 testing for UCS. Eighty-nine specimens from 84 patients with metastatic/recurrent UCS were prospectively collected from May 2018 to July 2020. We performed HER2 immunohistochemistry (IHC) for 89 specimens and FISH for 44 specimens. HER2 expression details and HER2 score were evaluated according to the latest ASCO/CAP criteria for gastric (2016) and breast cancer (2018). HER2 IHC scores according to the gastric cancer criteria were 0 in 31 cases (35%), 1+ in 26 (29%), 2+ in 22 (25%), and 3+ in 10 cases (11%) of the 89 specimens. A lateral/basolateral membranous staining pattern was observed in 28/32 (88%) specimens with HER2 scores of 2+/3+. HER2 intratumoral heterogeneity was identified in 28/32 (88%) of the specimens with HER2 scores of 2+/3+. The overall concordance rate of HER2 score was 70% between the gastric and breast criteria. FISH revealed HER2 gene amplification in 10/44 (23%) specimens containing only lateral/basolateral membranous staining pattern. Based on the histopathological features of HER2 expression in UCS, a scoring system that accepts lateral/basolateral staining patterns should be applied. Furthermore, we proposed specific requirements for UCS testing, including specimen selection, scoring system, and calculating the proportion of HER2-positive cells.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Pradhan TS, Stevens EE, Ablavsky M, Salame G, Lee YC, Abulafia O (2011) FIGO staging for carcinosarcoma: can the revised staging system predict overall survival? Gynecol Oncol 123(2):221–224. https://doi.org/10.1016/j.ygyno.2011.08.007

    Article  PubMed  Google Scholar 

  2. Fujii H, Yoshida M, Gong ZX, Matsumoto T, Hamano Y, Fukunaga M, Hruban RH, Gabrielson E, Shirai T (2000) Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 60(1):114–120

    CAS  PubMed  Google Scholar 

  3. Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilguvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD (2016) Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 113(43):12238–12243. https://doi.org/10.1073/pnas.1614120113

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ (2000) Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 88(12):2782–2786. https://doi.org/10.1002/1097-0142(20000615)88:12<2782::aid-cncr17>3.0.co;2-k

    CAS  Article  PubMed  Google Scholar 

  5. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA (2007) Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 31(11):1653–1661. https://doi.org/10.1097/PAS.0b013e3181161ba3

    Article  PubMed  Google Scholar 

  6. Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, Vergote I (2004) ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol 95(3):583–587. https://doi.org/10.1016/j.ygyno.2004.07.041

    CAS  Article  PubMed  Google Scholar 

  7. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA (2006) EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 100(1):101–106. https://doi.org/10.1016/j.ygyno.2005.07.124

    CAS  Article  PubMed  Google Scholar 

  8. Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM, Greer BE, Muntz HG, Goff BA (1996) The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol 60(1):81–88. https://doi.org/10.1006/gyno.1996.0015

    CAS  Article  PubMed  Google Scholar 

  9. Saglam O, Husain S, Toruner G (2013) AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma. Int J Gynecol Pathol 32(5):493–500. https://doi.org/10.1097/PGP.0b013e31827fedef

    CAS  Article  PubMed  Google Scholar 

  10. Rottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N (2020) HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Mod Pathol 33(1):118–127. https://doi.org/10.1038/s41379-019-0358-x

    CAS  Article  PubMed  Google Scholar 

  11. Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD (2018) Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 36(20):2044–2051. https://doi.org/10.1200/JCO.2017.76.5966

    CAS  Article  PubMed  Google Scholar 

  12. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP (2002) Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 8(5):1271–1279

    CAS  PubMed  Google Scholar 

  13. Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S (2019) Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol 20(6):816–826. https://doi.org/10.1016/S1470-2045(19)30097-X

    CAS  Article  PubMed  Google Scholar 

  14. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K, Investigators DE-G (2020) Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382(25):2419–2430. https://doi.org/10.1056/NEJMoa2004413

    CAS  Article  PubMed  Google Scholar 

  15. Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T (2016) DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22(20):5097–5108. https://doi.org/10.1158/1078-0432.CCR-15-2822

    CAS  Article  PubMed  Google Scholar 

  16. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T (2016) Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 107(7):1039–1046. https://doi.org/10.1111/cas.12966

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. Yonemori K STATICE trial, https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033713 accessed on 27, September, 2020

  18. Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S (2020) Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol 38(17):1887–1896. https://doi.org/10.1200/JCO.19.02318

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35(4):446–464. https://doi.org/10.1200/JCO.2016.69.4836

    CAS  Article  PubMed  Google Scholar 

  20. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36(20):2105–2122. https://doi.org/10.1200/JCO.2018.77.8738

    CAS  Article  PubMed  Google Scholar 

  21. Buza N (2020) HER2 testing in endometrial serous carcinoma. Arch Pathol Lab Med. https://doi.org/10.5858/arpa.2020-0207-RA

  22. Rottmann D, Assem H, Matsumoto N, Wong S, Hui P, Buza N (2020) Does specimen type have an impact on HER2 status in endometrial serous carcinoma? Discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent intratumoral heterogeneity. Int J Gynecol Pathol Publish Ahead of Print. https://doi.org/10.1097/PGP.0000000000000690

  23. Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25(5):637–650. https://doi.org/10.1038/modpathol.2011.198

    CAS  Article  PubMed  Google Scholar 

  24. Yoshida H, Yamamoto N, Taniguchi H, Oda I, Katai H, Kushima R, Tsuda H (2014) Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch 465(2):145–154. https://doi.org/10.1007/s00428-014-1597-3

    CAS  Article  PubMed  Google Scholar 

  25. Buza N, English DP, Santin AD, Hui P (2013) Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol 26(12):1605–1612. https://doi.org/10.1038/modpathol.2013.113

    CAS  Article  PubMed  Google Scholar 

  26. Buza N, Roque DM, Santin AD (2014) HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med 138(3):343–350. https://doi.org/10.5858/arpa.2012-0416-RA

    Article  PubMed  Google Scholar 

  27. Kurman RJ, Carcangiu ML, Young RH, Herrington CS (2014) WHO classification of tumours of female reproductive organs. International Agency for Research on Cancer

  28. Yoshida H, Shimada K, Kosuge T, Hiraoka N (2016) A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. Virchows Arch 468(4):431–439. https://doi.org/10.1007/s00428-015-1898-1

    CAS  Article  PubMed  Google Scholar 

  29. Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, Yamada T, Kikuchi Y, Honjo H, Matsubara O (2003) Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci 94(11):986–991. https://doi.org/10.1111/j.1349-7006.2003.tb01389.x

    CAS  Article  PubMed  Google Scholar 

  30. Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, Marchionni M, Scarselli G, Taddei GL (2005) COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol 96(1):159–167. https://doi.org/10.1016/j.ygyno.2004.09.050

    CAS  Article  PubMed  Google Scholar 

  31. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24(15):2376–2385. https://doi.org/10.1200/JCO.2005.03.4827

    CAS  Article  PubMed  Google Scholar 

  32. Cimbaluk D, Rotmensch J, Scudiere J, Gown A, Bitterman P (2007) Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol 105(1):138–144. https://doi.org/10.1016/j.ygyno.2006.11.001

    CAS  Article  PubMed  Google Scholar 

  33. McCluggage WG (2002) Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 12(6):687–690. https://doi.org/10.1046/j.1525-1438.2002.01151.x

    CAS  Article  PubMed  Google Scholar 

  34. Hanna W, Nofech-Mozes S, Kahn HJ (2007) Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event. Breast J 13(2):122–129. https://doi.org/10.1111/j.1524-4741.2007.00396.x

    CAS  Article  PubMed  Google Scholar 

  35. Lee HE, Park KU, Yoo SB, Nam SK, Park DJ, Kim HH, Lee HS (2013) Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 49(6):1448–1457. https://doi.org/10.1016/j.ejca.2012.10.018

    CAS  Article  PubMed  Google Scholar 

  36. Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD (2015) T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clin Exp Metastasis 32(1):29–38. https://doi.org/10.1007/s10585-014-9688-8

    CAS  Article  PubMed  Google Scholar 

  37. Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, Masserdotti A, Zammataro L, Altwerger G, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD (2017) SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/Neu expression. Clin Cancer Res 23(19):5836–5845. https://doi.org/10.1158/1078-0432.CCR-16-2862

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. Han C, Altwerger G, Menderes G, Haines K, Feinberg J, Lopez S, Manzano A, Varughese J, Santin AD (2018) Novel targeted therapies in ovarian and uterine carcinosarcomas. Discov Med 25(140):309–319

    PubMed  Google Scholar 

Download references

Code availability

Not applicable.

Funding

This study was supported by the Japan Agency for Medical Research and Development (AMED), “Clinical research and clinical trial promotion research project Cancer research and development expenses (28-A-12).” The STATICE trial was funded by the Japan Agency for Medical Research and Development (AMED), and Daiichi Sankyo Co., Ltd. DS-8201a was provided by Daiichi Sankyo Co., Ltd.

Author information

Author notes

  1. Hiroshi Yoshida and Tadaaki Nishikawa contributed equally to this work.

Affiliations

  1. Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Hiroshi Yoshida

  2. Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Tadaaki Nishikawa & Kan Yonemori

  3. Medical Oncology Division, Ambulatory Chemotherapy Center, Hyogo Cancer Center, Kitaoji-cho, Akashi, Hyogo, Japan

    Koji Matsumoto

  4. Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Aichi, Japan

    Masahiko Mori

  5. Division of Gynecology, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan

    Yasuyuki Hirashima

  6. Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Minamiumemoto-machi, Matsuyama, Ehime, Japan

    Kazuhiro Takehara

  7. Gynecology Service, National Hospital Organization Kyushu Cancer Center, Minami-ku, Fukuoka, Japan

    Kazuya Ariyoshi

  8. Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Yamane, Hidaka, Saitama, Japan

    Kosei Hasegawa

Authors
  1. Hiroshi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tadaaki Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahiko Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasuyuki Hirashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhiro Takehara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuya Ariyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kosei Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kan Yonemori
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Hiroshi Yoshida: conceptualization, methodology, formal analysis, investigation, resources, data curation, writing (original draft), and writing (review and editing). Tadaaki Nishikawa: formal analysis, resources, data curation, and writing (review and editing). Koji Matsumoto: resources, data curation, and writing (review and editing). Masahiko Mori: resources, data curation, and writing (review and editing). Yasuyuki Hirashima: resources, data curation, and writing (review and editing. Kazuhiro Takehara: resources, data curation, and writing (review and editing). Kazuya Ariyoshi: resources, data curation, and writing (review and editing). Kosei Hasegawa: resources, data curation, and writing (review and editing. Kan Yonemori: resources, data curation, and writing (review and editing)

Corresponding author

Correspondence to Hiroshi Yoshida.

Ethics declarations

All study participants provided informed consent, and the present study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice, and with approved protocols (2014-393) by the institutional Review Board of the National Cancer Center, Tokyo, Japan.

Conflict of interest

The authors declare that they have no competing interests.

Consent to participate

All study participants provided informed consent.

Consent for publication

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Fig. 1
figure 3

Evaluation of histopathological details of HER2 expression in uterine carcinosarcoma (PNG 2839 kb)

Full size image

High resolution image (TIF 3494 kb)

ESM 2

(DOCX 23 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yoshida, H., Nishikawa, T., Matsumoto, K. et al. Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. Virchows Arch 478, 1161–1171 (2021). https://doi.org/10.1007/s00428-021-03017-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-021-03017-5

Keywords

  • Uterine carcinosarcoma
  • HER2
  • Immunohistochemistry
  • Scoring system
  • Gastric cancer
  • Breast cancer